To perform a comparative study of 500 consecutive 125 I seeds implants for intracapsular prostate carcinoma with two techniques differing in terms of both strand implantation and planning.
Purpose
Permanent low-dose-rate brachytherapy (LDR-BT) has become a standard treatment for localized prostate cancer, achieving ten-year biochemical relapse-free survival (bRFS) comparable to radical prostatectomy (RP) [1] [2] [3] [4] , and better than external beam radiation therapy (EBRT) [5] . Both, LDR-BT and RP are considered equivalent, while lacking randomized studies [6, 7] . Excellent results with radio active seeds at fifteen years of follow up have now been published [8, 9] .
The implant technique has evolved greatly [10] , achieving good results with loose or stranded seeds, and different forms of seed placement, as described in the American [11] and European [12, 13] recommendations. The use of real-time systems has improved bRFS in some series [14] . In this paper we review the experience of a single center comparing 500 consecutive implants in localized prostate carcinoma,withtwodifferenttechniques.Thefirst250patients were treated with stranded seeds (RapidStrand™) according to a preplanning dosimetry system, and the other half with real-time planning and a quick system to prepareanddecideseedpositionswithgreaterflexibility in seed distribution with different distances between them (Bard Prolink™). The Pro-Link system also uses linked seeds with the difference that spacers of different lengths can be used to prepare custom strands.
The aim of this study was to compare the two different techniques in a single center to know our own expe-rience, to evaluate whether the optimized technique can improve results and achieve high quality implants, and to know which changes we can do to get a better outcome.
Material and methods
From December 2002 to October 2007 we performed 250 implants with LDR 125 I seeds brachytherapy with RapidStrand™ and a preplanning system and from November 2007 to December 2010, 250 implants were performed with real-time planning and the Bard Pro-Link™ system. Nine patients were lost at the beginning of the follow-up and seven were excluded because they died ofnon-relateddiseasesinthefirsttwoyearsandarenot included in the analysis. Therefore, we compare 250 consecutive patients with the first system and 250 with the more recent technique. All cases were treated by the same clinical team. All patients had biopsy proven diagnostic of adenocarcinoma. In each group, mean age was 68 and 66, respectively, median PSA (prostate-specific antigen) was 7.3 and 7.2 ng/dl and Gleason score was ≤6in96% and86%.ThetumourstagewasT1-T2ain98%and94%. According to the D'Amico classification, modified with the recommendations of EORTC [13] , low risk cases (PSA < 10, Gleason 2-6, T1-T2a stage) were 80.8% and 71.2%. Intermediate risk cases (PSA 10-20, Gleason 7, T2b-c stage) were19.2%and27.6%.Nohighriskcases(PSA>20,Gleason 8-10, T3) were treated with the preplanning system and only 3 patients without extracapsular involvement with the real-time system. Patient characteristics are described in Table 1 , showing that the second group treated with real-time technique had younger men, more intermediate risk patients, and T2b stage, higher Gleason, less hormonal treatment and more cases of combined treatment with EBRT. Other inclusion criteria were life expectancy of more than 5 years, International Pros- The prescribed minimal peripheral dose was 145 Gy to the prostate volume. In some intermediate-risk cases, a combined approach with EBRT 46 Gy on the prostate and seminal vesicles, followed by 108 Gy peripheral dose by implant was used. More cases received this combined treatmentinthereal-timegroup(26%vs.73%).Twocases of each group had technical complications during the implant and less seeds than planned were inserted, and additional EBRT was given.
Hormonaltreatment(HT)wasgivento42%and28% ineachgroupduring3-6months;inonly10%ofthewhole population, the HT was given to reduce prostate volume in order to achieve a better distribution of the needles and avoid pubic arch interference. The other cases came to our department with HT prescribed by their urologists. Biochemical failure (BF) was defined according to the Phoenix criteria.
With the preplanning system, a volume study was performed and recorded 3-4 weeks before the implant date. A theoretical optimal distribution of the seeds was calculated using the Variseed 7.0 planning system, to achieve V 100 >98%andD 90 >145Gy(D 90 >108Gywhen used as a boost combined with EBRT). Constraints were urethral V 150 < 1% and rectal V 100 < 5%. On the day of the implant, the position of the prostate at the time of the volume study was reproduced prior to needle insertion, which was undertaken with transrectal ultrasound guidance and fluoroscopy. Technical and dosimetric details have been previously described [15] . With the real-time and Bard Pro-Link™ system, a volume study was performedseveralweeksbeforetheimplanttoconfirmthe suitabilityandvolumeoftheprostate.WeusedtheVariseed 8.0 planning system, to achieve the required dosimetric parameters. In both cases, if the volume was >50cc,HTwasgivenandthevolumestudywasrepeated three months later. The seeds model was the same but the visibility of the seeds and spacers was better with the Pro-Link™ system.
The day after the implant, the patient was discharged and one month later a planning CT was done for the definitivedosimetry.APSAbloodtestwastakenevery threemonthsduringthefirstyear,everyfourmonthsin thesecondyear,andeverysixmonthsuntilthefifthyear of follow-up, and yearly afterwards. Toxicity was graded according the RTOG/EORTC scales and sexual function with the National Cancer Institute scale. The Kaplan-Meier method was used to evaluate bRFS.
Results
Themedianfollow-upforthefirstgroupofpatients was48months(range24-84)and14cases(5.7%)hadbiochemical failure (BF), seven with a positive prostate biopsy,fivewithanegativebiopsy,andtwotreatedwithHT without biopsy. Mean age in these cases was 66 (range 59-73). Mean time to relapse was 41 months (range 9-84). Biochemicalrelapse-freesurvivalat5yearswas90.2%,in lowriskcasesthiswas91.3%andinintermediateriskcas-es84.2%.NodifferencesaccordingtoGleasonorTstage were seen but when presenting PSA was ≤ 10, bRFS was91.6%comparedwith79.9%incaseswithPSA>10 (p = 0.08) ( Table 2) .
The median follow-up for the second group of patients treated with real-time was 47 months (32-70) and 7cases(2.8%)hadBF,threewithdistantmetastasis,two with a negative prostate biopsy, and two without biopsy, treated with HT. Mean age in these cases was 71 (range 64-74). Biochemical relapse-free survival at 5 years was 97.2% (low-risk cases: 97.2%, intermediate-risk cases 97.1%). No differences according to Gleason, T stage or PSA were detected.
When comparing both groups, bRFS was always superior in the group of real-time technique but with the Kaplan-Meyermethod,nostatisticalsignificant(n.s.)differenceswereachievedatfiveyears.Consideringthewhole group of 500 patients, no statistical differences were seen comparing Gleason 6 versus 7, T1 stage versus T2, PSA until 10 ng/dl or over 10, hormonal treatment versus no blockade, and exclusive brachytherapy versus combined treatment using EBRT. The only variable that achieved asignificantdifference(p < 0.05) was in cases treated with Spikes of PSA over nadir plus 2 ng/dl (false relapses or PSA bounces) were seen in 11 of the first group and 5 of the second group, at a median time of 24 months, which went down to low levels without further treatment.Mediantimetotruerelapsesinthefirstgroupwas 41 months and in the second group 24 months.
Hormonal treatment had no influence on PSA controlinbotharms.Inthefirstgroup,bRFSwas88.3%with hormonalblockadeand91.7%withoutHT(n.s.),andin thesecondgroupwere97.1%and97.2%,respectively.We have compared hormonal blockade in all low risk cases versus intermediate risk cases and no differences were achieved. In cases with intermediate risk, 74 without hor-monaltreatmenthada5-yearbRFSof96.7%and40with hormonalblockade85.8%(n.s.).
LaterectaltoxicitywasG1-2rectalbleedingin3.6%of thefirstgroupand5.6%ofthesecondgroup,therewas noG3-4toxicity.GenitourinarytoxicitywasG1-2in4.6% ofthefirstgroupand12%inthesecondgroup,andG3-4 in1.9%and4.8%,respectively.Thiswasmainlyrelatedto urinaryretentionrequiringcatheterin6.5%ofpatientsin thefirstgroupand9.6%inthesecondone.Only1.9%and 4.4%requiredTURPrespectively.Self-limitinggrade1-2 urinarybleedingwasrecordedin4.8%andincontinence in 2% of the second group but none of the first group, and one case of G4 toxicity was registered resulting in a salvage cistectomy five years after the implant, because of bladder contraction with poor functional effects. The rate of complications was doubled when a combined treatment with EBRT plus BT was used compared with exclusive BT. In the second group, 195 patients received exclusive brachytherapy and the rate of rectal bleeding was3.6%,urinarybleeding3.6%andincontinence1.5%. The 55 patients treated with a combined approach, EBRT plusBT,hadarateof12.7%,7.2%,and3.6%,respectively. The rate of patients that required urinary catheter or TURP was not influenced by EBRT. Sexual function in previouslyactivepatientswaspreservedinaround60% of both groups.
Regarding dosimetric data, calculated in a representative group of 80 patients based on the planning CT one month after the implant, the median volume of the prostate receiving the 100% of the dose (V 100 ) increased from 89% to 93% with preplanning and real-time technique.Themediandosetothe90%oftheprostate(D 90 ) was 143 Gy and 157 Gy, respectively. When calculated from the ultrasound at the end of the implant in the operating room, V 100 was97%andD 90 was 171 Gy for patients receiving brachytherapy alone using the real-time technique.Thisdiscrepancycanbeduetothedifficultyto draw the real size of the prostate in the CT images, usually larger than the size using the ultrasound.
Discussion
Permanent LDR brachytherapy for prostate carcinoma achieves a ten-year bRFS of 87-96% in low risk cases and 63-86% in intermediate cases. In a study on 1313 patients, 48% of them with EBRT, 7-year bRFS was98%inlowriskand93%inintermediatecases [16] . The 20-year experience at Mount Sinai Medical Center, on 2495 patients treated for localized prostate cancer with brachytherapy or combined treatment with EBRT, resulted in 12-year bRFS of 90%, 84%, and 64% in low, intermediate, and high risk cases [17] . A selection of 1656 cases with high-quality brachytherapy treated in theUniversityofWashington,Seattle,achievedexcellent long-term outcomes, with12-year bRFS of 98.6%, 96.5%, and 90.5%, respectively, results that compare favorably to alternative treatment modalities including prostatectomy [18] . We have compared two different techniques in 500 consecutive patients treated at a single institution by the same team. Median follow up is 4 years, it is a short term experience to draw conclusions but bRFS is always favoring the second technique, even if the differencesarenotstatisticallysignificant.Withthefirsttechnique using RapidStrand™ and a preplanning system, weachievedfive-yearbRFSof92%inlowriskcasesand 86%inintermediatecases.Withthesecondtechniqueusing a real-time technique and the ProLink™ system, we achievedover97%inbothgroups.Ofcourse,thelearning curve could have some influence in the outcome of the firstgroupbuttheresultsofthesecondgrouparegood enough, comparing other published papers, especially in intermediate risk cases. EBRT was used in intermediate casesinonequarterofthefirstgroupandthreequarters of the second group. The dosimetric results are better using the real-time technique, which enables calculation of Fig. 1 . Ultrasound image with real-time technique and Bard Pro-Link™ system. The distance between seeds is maintained by spacers, which are visible even clearly than seeds the actual dose during the implant and allows for insertion of extra seeds when needed. The ProLink™ system isveryflexibleallowing the useofconsecutiveorseparatedlinkedseedswitharigidfixation(Figure1),stable for at least six months, achieving better dosimetric isodose curves during the calculation in the operating room, and one month later in the CT, when less movement and misplacement of seeds was observed, remaining in place (Figure 2 and 3) . A one-stage prostate brachytherapy technique (4D brachytherapy) using a combination of strandedandlooseseedsshowedsignificantlyimproved dosimetry [19] .Withthistechnique,dosimetryattheend of the implant is excellent and we consider this is the reason for the improvement in the bRFS equivalent to the best published series [20] . Longer follow up will be requiredtoconfirmlongtermoutcome.
Gooddosimetricparametersinthedefinitivedosimetry done one month after the implant are related to better prognosis. At the Memorial Sloan Kettering Cancer Center, a D 90 >140Gywastheonlypredictivefactorin 558 intermediate-risk patients who achieved a ten-year bRFS of 93% [21] . At the Mount Sinai School of Medicineinlow-riskcases,eight-yearbRFSwas94%withD 90 ≥140Gycomparedto75%withD 90 < 140 Gy [22] , and in Leeds, the experience was similar [23] . Other studies point to a dose-response above and below 150 Gy [24] . In our study we have improved the D 90 from 143 Gy to 157 Gy with the new technique [25] and the outcome shows the importance of these high doses for local control.Infact,thefirstgrouphadsuboptimalimplantswith 50%havinglessthantheprescriptiondose.Areviewof 2693 patients from eleven centers reported that the D 90 wasthebestwaytodefineagoodqualityimplant [26] .On thisbasisweexpectourbetterresultsatfiveyearsoffollow-up with real time implant dosimetry to be maintained long term. If post-implant dosimetry is within the optimal range, distant rather than local failure appears to be the main cause of BF [27] , and that is our own experience.
Hormonal blockade, most times prescribed by an urologist previously to the implant, has shown no usefulness as described in other studies like series of the Mount Sinai School of Medicine [22] or Leeds [28] . Results of a cohort of200hormone-naïvepatientshadabRFSof95.6%atfive years [29] ,inourstudyover97%isachievedwithoutHT, therefore, we consider that it is no longer required except in order to decrease a big prostate volume, over 50-60 cc.
Several factors can influence the outcome [12] , and in the first group using the pre-planning system, PSA >10ng/dlwasanegativeprognosticfactorbutusingthe real-time technique this was not a predictive, although, in this group most of the cases were treated with a combined approach with EBRT. A young age is considered an indication for radical prostatectomy in some centers. In our study, only one out of 22 patients younger than 60yearsoldrelapsedinthefirstgroupandnoneofthe 40 cases of the second group; furthermore, most of these have their sexual potency preserved. The Mount Sinai MedicalCenterconfirmedinastudyinmenaged60or less that permanent LDR implants offer an excellent biochemical control at 8 years of follow-up, comparable to older men [30] , with potency preservation [31, 32] .
Prostate-specificantigenbouncesovernadir+2ng/dl, considered as "false relapses", were seen at a median of twoyearsaftertheimplantin3.2%ofthetotalpopulation; the median time to true relapses was 41 months in the firstgroupbutonly24monthsinthesecondgroup.This difference may be explained by predominance of distant metastatic relapse in the second group with no proven local recurrences. It would be expected that local recurrences will require more time to develop, and since no local recurrences occurred with the real-time technique, the median time to relapse is shorter. A study from Toronto showed that in 292 patients the median time to biochemical control was 30 months, and therefore, any PSA bounce during the first two years should be observed without starting treatment [33] . The complication rate both rectal and genitourinary was increased in the second group. This may be explained by higher median dose to the prostate and the larger num-berofpatientstreatedwithEBRT.Nevertheless,the4.8% incidence of G3-4 late complications is considered acceptable when balanced against the very high rate of biochemical control, which is comparable to the best published series [34] . The addition of EBRT in intermediate-risk cases was possibly responsible for the higher rate of G1-2 urinary and rectal bleeding. It is probable that some cases of intermediate risk disease can be managed with exclusive brachytherapy [35] , because the D 90 is almost always higher than 145 Gy, and the implants with real time technique have an excellent dosimetry. It is important to point at the fact that the D 90 is 115-120% of the planned prescription dose with the real time technique, and maybe this increase of dose is necessary to achieve an appropriate final D 90 . A higher dose, over 170 Gy covering a 3 mm margin can be a good option to be considered. And this approach may decrease complications in the future, avoiding EBRT. In fact, we have decided to treat intermediate-low risk cases as Gleason 3+4 with exclusive brachytherapy.
Therefore, a better outcome in prostate LDR-BT can be expected if a good dosimetry with high D 90 can be achieved, and probably, in this situation, a hormonal blockade could not be necessary. Every center should knowtheownresultsandtrytofindthebesttechnique and practice without increasing the complications rate. In our experience, the real-time implantation and a good system to build the linked seeds offers excellent bRFS in prostate carcinoma.
Conclusions
The outcome of patients with low risk prostate carcinoma treated with 125 I seeds is very good with a low complication rate. Hormonal treatment has no impact on the outcome and is not indicated. The real-time approach in our hands achieved a more precise seed implantation, betterdosimetry,andastatisticallynon-significantbetter biochemical control at the price of an increased toxicity. Wehavemadethisourstandardtechnique.Intheintermediate risk group a combined treatment approach of EBRT and brachytherapy may be necessary to give the best outcome.
